Psychedelic Drugs Market Size, Growth Trends and Forecast 2026–2035
According to Shivani Zoting, who specializes in pharmaceutical and biotechnology market research, with 5+ years of experience in market research and industry analysis. My research indicates that the Psychedelic Drugs Market is set to grow from USD 6.68 billion in 2026 to USD 23.14 billion by 2035, driven by rising demand for innovative mental health treatments and expanding clinical development activities. I found that psilocybin, depression-focused therapies, oral formulations, hospitals, and psychedelic-assisted therapy represent the leading market segments, while North America maintains market leadership and Asia Pacific shows the strongest growth potential. The competitive landscape features companies such as Compass Pathways, Seelos Therapeutics, atai Life Sciences, GH Research, Johnson & Johnson, and Numinus Wellness, all advancing product development and commercialization strategies across the sector.
Last Updated : 16 July 2026
Category: Biotechnology
Insight Code: 6885
Format: PDF / PPT / Excel